Core Points - The company has established guidelines for the upcoming shareholders' meeting to ensure order and efficiency [1][2] - The meeting will combine on-site and online voting methods, with specific time slots for each [3][4] - The company plans to amend its articles of association to eliminate the supervisory board and transfer its responsibilities to the audit committee [4][5] Meeting Procedures - Shareholders must register and sign in before the meeting starts, and latecomers will not be allowed to vote [1][2] - Each shareholder's speech should be concise and limited to five minutes, focusing on the meeting's agenda [2] - Voting can be conducted either on-site or online, but not both for the same share [2][3] Agenda Items - The agenda includes proposals for revising the fund management system to prevent the controlling shareholder from occupying company funds [4] - Proposals for the election of the fourth board of directors, including both non-independent and independent director candidates [4] - A proposal to amend the company's articles of association to abolish the supervisory board [4][5] Voting and Counting - Voting will be conducted by a lawyer representative, and shareholders with conflicts of interest will not participate in the counting [3] - The voting times for the online platform are set for specific periods on the day of the meeting [3] - The results of the on-site voting will be announced by the meeting host [3]

Market Overview - The personal care products sector rose by 2.89% on September 4, with Jieya Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Jieya Co., Ltd. (301108) closed at 34.40, up 13.16% with a trading volume of 72,700 shares and a turnover of 243 million yuan [1] - Yiyi Co., Ltd. (001206) closed at 26.72, up 10.00% with a trading volume of 131,800 shares and a turnover of 342 million yuan [1] - Dengkang Oral Care (001328) closed at 43.55, up 7.40% with a trading volume of 53,000 shares and a turnover of 226 million yuan [1] - Other notable performers include Ziya Co., Ltd. (003006) up 5.13%, and Liangmian Needle (600249) up 3.29% [1] Capital Flow - The personal care products sector saw a net inflow of 56.24 million yuan from institutional investors, while retail investors experienced a net outflow of 6.89 million yuan [2] - The main capital inflow was observed in Yiyi Co., Ltd. with 64.76 million yuan, while the largest outflow was from Jieya Co., Ltd. with 22.08 million yuan [3] Individual Stock Analysis - Jieya Co., Ltd. had a main capital inflow of 3.69 million yuan, but retail investors showed a net outflow of 22.07 million yuan [3] - Dengkang Oral Care experienced a net outflow of 4.13 million yuan from main capital, while retail investors had a net inflow of 14.52 million yuan [3] - Ziya Co., Ltd. had a net inflow of 3.36 million yuan from main capital, with a slight outflow from retail investors [3]

2025 年第一次临时股东会会议资料 倍加洁集团股份有限公司 PERFECT GROUP CORP.,LTD （江苏省扬州市杭集工业园） 2025 年第一次临时股东会会议资料 1 2025 年第一次临时股东会会议资料 倍加洁集团股份有限公司 2025 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证股 东会的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司股东会规则》以及《倍加洁集团股份有限公司章程》等相关规定，倍 加洁集团股份有限公司（以下简称"公司"）特制定本次股东会会议须知，请出 席股东会的全体人员自觉遵守。 1、本次会议设会务组，由公司董事会秘书负责会议的程序安排和会务工作。 2、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，务必 请出席会议的股东或股东代理人（以下统称"股东"）及相关人员准时到达会场 签到确认参会资格。股东在参会登记时间内没有通过现场或信函方式登记的，不 在签到表上登记签到的，或会议正式开始后没有统计在会议公布表决权数量之内 的股东，不得参加表决。 3、出席会议的股东依法享有发言权、表决权等各项权利 ...

Market Overview - The personal care products sector experienced a decline of 1.87% on September 1, with Haoyue Care leading the drop [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Notable stock performances include: - Yiyi Co., Ltd. (001206) closed at 25.98, up 2.81% with a trading volume of 91,800 shares and a turnover of 238 million yuan [1] - Haoyue Care (605009) closed at 36.35, down 10.00% with a trading volume of 111,800 shares and a turnover of 408 million yuan [2] - Zhongshun Jierou (002511) closed at 8.64, down 1.48% with a trading volume of 186,900 shares and a turnover of 162 million yuan [2] Capital Flow - The personal care products sector saw a net outflow of 147 million yuan from institutional investors, while retail investors experienced a net inflow of 98.24 million yuan [2] - The capital flow for individual stocks shows: - Ziya Co., Ltd. (003006) had a net inflow of 6.03 million yuan from institutional investors [3] - Haoyue Care (605009) had a significant net outflow of 622.31 million yuan from institutional investors [3]

Core Viewpoint - The company Enkang Biotechnology, a subsidiary of Beijiajie, has received FDA-GRAS certification for its probiotic strain BC01, marking it as the first Chinese company to achieve this certification with the specific strain [1][2]. Company Overview - Beijiajie primarily engages in the research, production, and sales of oral hygiene products, disposable sanitary products, and probiotic products, including probiotic raw materials and consumer goods [2]. - Enkang has established two research centers in Suzhou and XuZhou, employing over 40 professionals with master's and doctoral degrees, and has developed a proprietary strain library containing over 12,000 strains [3]. Product Details - The BC01 strain has been authorized with 8 domestic and international patents and has undergone 4 human clinical studies, targeting health issues such as constipation, immune enhancement, and metabolic regulation [2][3]. - The probiotic BC01 can be utilized in various functional food products, beverages, gummies, and snacks, aligning with the growing demand in the health food market [2]. Financial Performance - In the first half of 2025, Beijiajie reported a revenue of 717 million yuan, a year-on-year increase of 15.64%, and a net profit attributable to shareholders of 43.52 million yuan, reflecting a growth of 31.31% [2]. Market Implications - The FDA-GRAS certification signifies that the quality and safety of the BC01 strain meet international standards, allowing for potential exports to the U.S. and other markets recognizing the GRAS certification, which is expected to positively impact Enkang's performance [3].

Core Viewpoint - The company Enkang Biotechnology, a subsidiary of Beijiajie, has received FDA-GRAS certification for its probiotic strain BC01, marking it as the first Chinese company to achieve this certification with the Weizmannia coagulans strain, which is considered a significant milestone in food safety standards [1][2]. Company Overview - Beijiajie primarily engages in the research, development, production, and sales of oral hygiene products, disposable sanitary products, and probiotic products, including probiotic raw materials and consumer products [2]. - Enkang has established two research centers in Suzhou and XuZhou, employing over 40 professionals with master's and doctoral degrees, and has developed a proprietary strain library with over 12,000 strains [3]. Product and Market Potential - The BC01 strain has been authorized with 8 domestic and international patents and has undergone 4 human clinical studies, targeting health issues such as constipation, immune enhancement, micro-ecological regulation, lipid metabolism improvement, and anti-aging [2][3]. - The probiotic can be utilized in various functional food products, beverages, gummies, and snacks, aligning with the growing demand in the health food market [2]. Financial Performance - In the first half of 2025, Beijiajie reported a revenue of 717 million yuan, a year-on-year increase of 15.64%, and a net profit attributable to shareholders of 43.52 million yuan, reflecting a growth of 31.31% [2].

凝结魏茨曼氏菌BC01获得美国FDA-GRAS认定后，标志着产品质量和安全性得 到国际认可，可以出口到美国以及认可美国GRAS认证的其他国际市场，预计会对 善恩康业绩产生积极影响。截至目前，凝结魏茨曼氏菌BC01产生的收入占善恩康 整体营收比重较小，敬请投资者注意投资风险。 证券代码：603059 证券简称：倍加洁 公告编号：2025-049 倍加洁集团股份有限公司 关于控股子公司凝结魏茨曼氏菌BC01益生菌 获得美国FDA GRAS认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 倍加洁集团股份有限公司(以下简称"公司")近日获悉，控股子公司善恩康 生物科技（苏州）有限公司(以下简称"善恩康")具有自主知识产权的凝结魏茨 曼氏菌BC01益生菌（学名：凝结魏茨曼氏菌， Weizmannia coagulans ，曾用名： 凝结芽孢杆菌）通过美国食品药品监督管理局（Food and Drug Administration, FDA）审核，获得FDA-GRAS认证（Generally Recognized As Safe ...

Core Viewpoint - The company Beijiajie (603059.SH) announced that its subsidiary, Shanenkang Biotechnology (Suzhou) Co., Ltd., has received FDA-GRAS certification for its probiotic strain, Weissella confusa BC01, marking a significant compliance and quality achievement that meets international standards [1] Company Summary - Shanenkang becomes the first company in China to obtain FDA-GRAS certification for Weissella confusa [1] - The probiotic strain has been authorized with 8 domestic and international invention patents and has published 2 SCI papers [1] - The company has conducted 4 human clinical studies on the probiotic strain, indicating its potential for diverse applications in functional foods, beverages, gummies, and snacks [1] - The FDA-GRAS recognition is expected to have a positive impact on Shanenkang's performance [1]

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant increases in revenue and net profit compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 reached 717 million yuan, a year-on-year increase of 15.64% [1] - Net profit attributable to shareholders was 43.52 million yuan, up 31.31% year-on-year [1] - In Q2 2025, total revenue was 393 million yuan, reflecting a 17.65% increase year-on-year, while net profit surged by 119.08% to 31.11 million yuan [1] - Gross margin improved to 26.52%, an increase of 4.96% year-on-year, and net margin rose to 6.51%, up 26.37% [1] Cost and Efficiency Metrics - Total selling, administrative, and financial expenses amounted to 92.38 million yuan, accounting for 12.88% of revenue, which is a 13.05% increase year-on-year [1] - Earnings per share (EPS) increased by 30.3% to 0.43 yuan, while operating cash flow per share rose by 21.85% to 0.79 yuan [1] Debt and Cash Flow Analysis - The company’s cash and cash equivalents increased significantly by 111.53% to 127 million yuan [1] - Accounts receivable rose by 18.3% to 272 million yuan, while interest-bearing debt increased slightly by 2.88% to 720 million yuan [1] - The company’s cash flow situation is a point of concern, with cash to current liabilities ratio at 29.59% [3] Market Strategy and Future Outlook - The company is focusing on developing large customer accounts and has established framework agreements with overseas distributors for its KK probiotic products [4] - The sales strategy for 2025 includes monthly tracking of customer development and sales performance to enhance market penetration [4]

Summary of the Conference Call for Beijiajie Company Overview - **Company**: Beijiajie - **Period**: First half of 2025 - **Revenue**: 6.63 billion CNY, a year-on-year increase of 10.2% [2][9] - **Net Profit**: 435.2 million CNY, a year-on-year increase of 31.31% [3] - **Gross Margin**: Increased by 1.21 percentage points to 25% [11] Key Points Revenue Growth - **Total Revenue Growth**: After merging with Shanenkang, total revenue growth reached 15.6% [2] - **Domestic vs. Overseas**: Domestic business revenue grew by 29%, while overseas business slightly decreased by 0.1% [2][9] Product Performance - **Oral Care Products**: Revenue of 4.85 billion CNY, a year-on-year increase of 21% [4] - **Toothbrushes**: Revenue decreased by 4.81% to 2.38 billion CNY [4] - **Dental Floss**: Revenue increased by 35% to 707.5 million CNY [4] - **Toothpaste**: Significant growth due to partnerships with major clients [4] - **Wet Wipes**: Revenue of 1.78 billion CNY, a year-on-year decrease of 10.8%, but gross margin improved to 23.48% [5] - **Shanenkang Probiotics**: Revenue of 48.98 million CNY, a significant year-on-year increase, achieving a net profit of 8.38 million CNY [6][13] Brand Performance - **Self-owned Brand Beijiajie**: Revenue of 55.21 million CNY, a year-on-year increase of 36%, but still incurred a loss of 10.42 million CNY [8] - **E-commerce Performance**: 45% of online sales from Douyin, which is the main source of losses [8] Operational Insights - **OEM Business**: Revenue of 6.08 billion CNY, a year-on-year increase of 8% [7] - **Production Capacity Utilization**: Toothbrush capacity utilization at 70%, with plans to increase toothpaste production lines [21] Market Dynamics - **Impact of Tariff Policies**: April tariff policies temporarily affected orders and shipping, but the situation has normalized [23] - **Regional Performance**: European region saw over 20% growth, while the U.S. market faced challenges due to decreased demand for medical wet wipes [22] Future Outlook - **Revenue Guidance**: Aiming for double-digit growth, with a bottom line of 10% for the year [26] - **Investment in R&D**: Shanenkang's R&D investment ratio is expected to be over 15%, focusing on next-generation probiotics [19] Additional Notes - **Challenges**: The company faced its first loss in history this year, but plans to improve operational performance and provide returns to investors [27] Conclusion Beijiajie demonstrated solid revenue growth in the first half of 2025, driven by strong domestic performance and strategic partnerships. However, challenges in the overseas market and specific product lines, such as wet wipes and toothbrushes, highlight areas for improvement. The company remains focused on maintaining growth and enhancing profitability through strategic investments and operational efficiencies.